June 9 (Reuters) – The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Tuesday: GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)